等待開盤 12-25 09:30:00 美东时间
+0.160
+0.49%
今日重点评级关注:Ascendiant Capital:维持Society Pass"买入"评级,目标价从22美元升至22.5美元;HC Wainwright & Co.:维持Climb Bio"买入"评级,目标价从9美元升至11美元
12-19 10:15
今日重点评级关注:杰富瑞:维持ImmunityBio Inc Ordinary Shares"买入"评级,目标价从8美元升至9美元;B. Riley证券:维持WAVE Life Sciences"买入"评级,目标价从19美元升至37美元
12-15 15:30
UBS analyst Danielle Antalffy initiates coverage on PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy rating and announces Price Target of $62.
12-13 00:13
今日重点评级关注:Ascendiant Capital:维持GRI Bio"买入"评级,目标价从35美元升至36美元;Ascendiant Capital:维持Atossa Therapeutics"买入"评级,目标价从7.75美元升至8美元
12-09 10:32
今日重点评级关注:B. Riley证券:维持Seabridge Gold"买入"评级,目标价从50美元升至65美元;HC Wainwright & Co.:维持TRX Gold"买入"评级,目标价从1.2美元升至1.4美元
12-03 09:58
Morgan Stanley analyst Patrick Wood maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $56 to $51.
12-03 01:52
PROCEPT BioRobotics will present at the 37th Annual Piper Sandler Healthcare Conference on December 2, 2025, in New York City. A live webcast and archived recording will be available on the company’s website. PROCEPT BioRobotics, focused on advancing urology care, develops robotic solutions like the HYDROS Robotic System for Aquablation therapy, designed to treat BPH-related LUTS. The therapy offers effective, safe outcomes regardless of prostate...
11-20 21:03
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从3美元升至9美元;HC Wainwright & Co.:上调CervoMed评级至"买入",目标价从11美元升至25美元
11-06 09:55
Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $58 to $51.
11-05 23:26
Companies Reporting Before The Bell • Sequans Communications (NYSE:SQNS) is lik...
11-04 19:12